252 related articles for article (PubMed ID: 33077264)
1. Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Bass AKA; El-Zoghbi MS; Nageeb EM; Mohamed MFA; Badr M; Abuo-Rahma GEA
Eur J Med Chem; 2021 Jan; 209():112904. PubMed ID: 33077264
[TBL] [Abstract][Full Text] [Related]
2. Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery.
Seo SY
Arch Pharm Res; 2012 Feb; 35(2):197-200. PubMed ID: 22370774
[TBL] [Abstract][Full Text] [Related]
3. Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency.
Pan Y; Hou H; Zhou B; Gao J; Gao F
Eur J Med Chem; 2023 Dec; 262():115879. PubMed ID: 37875056
[TBL] [Abstract][Full Text] [Related]
4. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.
Chu-Farseeva YY; Mustafa N; Poulsen A; Tan EC; Yen JJY; Chng WJ; Dymock BW
Eur J Med Chem; 2018 Oct; 158():593-619. PubMed ID: 30243158
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
8. Anticancer properties of chimeric HDAC and kinase inhibitors.
Biersack B; Polat S; Höpfner M
Semin Cancer Biol; 2022 Aug; 83():472-486. PubMed ID: 33189849
[TBL] [Abstract][Full Text] [Related]
9. Recent progress in the development of histone deacetylase inhibitors as anti-cancer agents.
Zhang L; Lei J; Shan Y; Yang H; Song M; Ma Y
Mini Rev Med Chem; 2013 Dec; 13(14):1999-2013. PubMed ID: 24160707
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
[TBL] [Abstract][Full Text] [Related]
11. CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy.
Sun H; Mediwala SN; Szafran AT; Mancini MA; Marcelli M
Horm Cancer; 2016 Jun; 7(3):196-210. PubMed ID: 26957440
[TBL] [Abstract][Full Text] [Related]
12. Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
Chen J; Li Y; Zhang J; Zhang M; Wei A; Liu H; Xie Z; Ren W; Duan W; Zhang Z; Shen A; Hu Y
Eur J Med Chem; 2021 Jan; 209():112868. PubMed ID: 33077265
[TBL] [Abstract][Full Text] [Related]
13. Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
Dong G; Chen W; Wang X; Yang X; Xu T; Wang P; Zhang W; Rao Y; Miao C; Sheng C
J Med Chem; 2017 Oct; 60(19):7965-7983. PubMed ID: 28885834
[TBL] [Abstract][Full Text] [Related]
14. A structural insight into hydroxamic acid based histone deacetylase inhibitors for the presence of anticancer activity.
Rajak H; Singh A; Raghuwanshi K; Kumar R; Dewangan PK; Veerasamy R; Sharma PC; Dixit A; Mishra P
Curr Med Chem; 2014; 21(23):2642-64. PubMed ID: 23895688
[TBL] [Abstract][Full Text] [Related]
15. Oxazole-Bridged Combretastatin A-4 Derivatives with Tethered Hydroxamic Acids: Structure⁻Activity Relations of New Inhibitors of HDAC and/or Tubulin Function.
Schmitt F; Gosch LC; Dittmer A; Rothemund M; Mueller T; Schobert R; Biersack B; Volkamer A; Höpfner M
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658435
[TBL] [Abstract][Full Text] [Related]
16. The Development Process: from SAHA to Hydroxamate HDAC Inhibitors with Branched CAP Region and Linear Linker.
Yang F; Zhao N; Hu Y; Jiang CS; Zhang H
Chem Biodivers; 2020 Jan; 17(1):e1900427. PubMed ID: 31793143
[TBL] [Abstract][Full Text] [Related]
17. New kinase and HDAC hybrid inhibitors: recent advances and perspectives.
Waitman K; Parise-Filho R
Future Med Chem; 2022 May; 14(10):745-766. PubMed ID: 35543381
[TBL] [Abstract][Full Text] [Related]
18. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
Zhang L; Zhang Y; Mehta A; Boufraqech M; Davis S; Wang J; Tian Z; Yu Z; Boxer MB; Kiefer JA; Copland JA; Smallridge RC; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Apr; 6(11):9073-85. PubMed ID: 25940539
[TBL] [Abstract][Full Text] [Related]
20. Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer.
Hesham HM; Lasheen DS; Abouzid KAM
Med Res Rev; 2018 Sep; 38(6):2058-2109. PubMed ID: 29733427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
